| Literature DB >> 28547950 |
Sarinthorn Rakmanee1, Samart Pakakasama, Suradej Hongeng, Sirima Sanguansin, Acharawan Thongmee, Wanida Pongstaporn.
Abstract
Objectives: This study assessed associations of the miR196a2 (rs11614913) T>C polymorphism withsusceptibility to childhood acute lymphoblastic leukemia (ALL) and clinical outcomes. Materials andEntities:
Keywords: Acute lymphoblastic leukemia; miRNA; 196a2; polymorphism
Year: 2017 PMID: 28547950 PMCID: PMC5494224 DOI: 10.22034/APJCP.2017.18.4.1117
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Frequency Distribution of Selected Variables in Cases and Controls
| Demographic characteristics | ALL (%) n=104 | Controls (%) n=180 |
|---|---|---|
| Sex | ||
| Males | 65 (62.50) | 98 (54.44) |
| Females | 39 (37.50) | 82 (45.56) |
| Age at diagnosis | ||
| < 6 years | 64 (61.54) | 137 (76.11) |
| >6 years | 40 (38.46) | 43 (23.89) |
| Immunophenotype (n=101) | ||
| T cell | 12 (11.88) | - |
| Non T cell | 89 (88.12) | - |
| Early pre-B | 78 (87.64) | - |
| Pre-B | 10 (11.24) | - |
| Mixed | 1 (1.12) | - |
| Risk classification (n=91) | ||
| low risk | 41 (45.05) | - |
| Standard risk | 41 (45.05) | - |
| High Risk | 9 (9.90) | - |
MiR-196a2 T>C Genotypes Distribution and Allele Frequency in ALL And Controls
| Genotypes | ALL (%) n=104 | Controls (%) n=180 | OR (95%CI) | p-value |
|---|---|---|---|---|
| TT | 13 (12.50) | 53 (29.45) | 1.000 (Reference) | |
| TC | 43 (41.35) | 78 (43.33) | 2.248 | 0.024 |
| CC | 48 (46.15) | 49 (27.22) | 4.321 | 0 |
| TC+CC | 91 (87.50) | 127 (70.55) | 2.921 | 0.001 |
| Allele frequency | ||||
| 0.33 | 0.51 | |||
| 0.67 | 0.49 |
Odds ratio and p-value were calculated by comparison of control and ALL for TC, CC and CC+CT versus TT;
significant at the 0.05 level of significance
The Association between MiR196a2 T>C Genotypes and Clinico-Pathological Data of ALL Patients
| Demographic data | MiR-196a2 | p-value | |
|---|---|---|---|
| T/T | CT or CC | ||
| Sex (n=104) | |||
| Male | 9 | 56 | 0.592 |
| Female | 4 | 35 | |
| Age at diagnosis (n=104) | |||
| < 6 years | 7 | 57 | 0.542 |
| >6 years | 6 | 34 | |
| Initial WBC count (n=97) | |||
| <50,000 cell /µl | 6 | 73 | 0.625 |
| >50,000 cell /µl | 2 | 16 | |
| Immunophenotype (n=101) | |||
| T cell | 2 | 10 | 0.676 |
| Non T cell | 11 | 78 | |
| Early –pre-B | 10 | 68 | |
| Pre-B | 1 | 9 | |
| Mixed | 0 | 1 | |
| Risk classification (n=91) | |||
| High Risk | 2 | 7 | 0.399 |
| Low risk or Standard risk | 10 | 72 | |
| Low risk | 5 | 36 | |
| Standard risk | 5 | 36 | |
, p-value were calculated by comparison of genotypes between high risk and low risk or standard risk